tional epidemiological survey of drug use in pregnancy conducted from 1988 to 1990 in 148 maternity wards, representing the general delivery practices of 22 countries. Data on exposure of pregnant women to psychotropic drugs, the indications for their use and their correlation with maternal characteristics are reported.
The use of psychotropic drugs in pregnancy, as would be expected is one of the areas of medicine where subjective factors are most likely to play an important role. On the one hand, we have the mixture of unknown, ex post facts worries and bad methodology, which has characterised the problem of drug assessment in pregnancy [1, 2] , and on the other we have the atmosphere of ambiguity which has accompanied the massive diffusion of psychotropic drugs in society (even more than in medicine) [3] . The results are often statements and attitudes (from fear and prohibition to denial), which do not favour rational behaviour in prescribers and users [4] .
As is often the case for medical issues, which lie at the border between cultural and societal values, the response of research has not been of increased attention towards the problem: a thorough literature search as far back as the day after the thalidomide-induced epidemics of malformations [5, 6] (at that time a drug with psychotropic indications) produced only an handful of references [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] (Table 1) . It is apparent that, while documenting that the overall downward trend in the frequency of drug use also includes psychotropics, the data represent settings and populations which are scarcely comparable and do not af-ford information about the present situation in most countries, other than the three which have produced the epidemiological profile presented in the Table. The large epidemiological survey on Drug Use in Pregnancy (DUP), conducted under the auspices of WHO-EURO in 22 countries [18] [19] [20] , has provided an opportunity to look at this issue through a representative sample of women being delivered under routine circumstances of hospital care.
Methods and population samples
A total of 14,778 women from 148 maternity wards in 22 countries in four continents was enrolled over the same duration of index periods during [1988] [1989] [1990] . Europe represented the highest final population (10,258 from 121 wards), followed by Asia (2,602 women from 14 wards), Central and South America (1,078 women from 7 hospitals), and Africa (840 women from six hospitals). In each participating country a clinical pharmacology unit and/or an obstetrics department acted as the reference centre for a group of vokmteer hospitals representing various levels of care. The reference centre used randomisation techniques to ensure that the study population was closely representative of the health care offered in hospitals in that country. The numbers of deliveries enrolled by each unit varied considerably, with the majority (14 countries) accounting for more than 1.5 per 1000 annual births in the country (at least 10 % of the annual births in each participating hospital). Ireland, Costa Rica, Japan, Sri Lanka, United Kingdom, Brazil, Ghana and India enrolled less than 1.0 per 1000 annual births. According to a method which has been shown to be reliable for recall of pregnancy-related events, including drug exposure [21] , the randomly selected women were interviewed in the first week after delivery by trained medical and/or paramedical personnel, on the basis of a structured, standardised questionnaire, focusing on education, quality of care during pregnancy (timing and number of health checks, morbidity), smoking and drinking habits, and drug consumption. Cross-check questions (on specific "drug" exposure vs indications/problems requiring drugs) were asked for each trimester and overall to help recall: for each affirmative response to a drug question, the brand name of the prescribed or self-chosen product and the indication was requested. Information obtained from the questionnaires was supplemented with data from hospital records about obstetric history, present delivery (mode, plurality and gestational age) and information about the babies (sex, body weight, Apgar score, malformations, and other major pathological events).
To estimate how representative were, the collected data the rates for a few general variables for each country, such as contraception, mode of delivery, malformations at birth and breastfeeding, were compared with data collected by the representative unit from other specific surveys. Close agreement was found within individual hospitals/countries [20] .
The drug products were centrally coded, after careful crosschecking of their contents with the national coordinators, according to the International Pharmaceutical Research Group classifications [22] , with marginal adjustments for any products coming from one or the other market. In this report we have analysed all drug prescriptions classified as "psychotropic", namely benzodiazepines, antidepressants and neuroleptics.
According to the pre-defined aim of the DUP protocol, data are presented a) first as they relate to the total sample as one population ("women delivering in hospital"), b) then, as they represent the heterogeneity of the cultural and care settings in individual countries, or geographically and historically homogeneous groups of countries. Table 2 ).
•
Psychotropic drugs; [] Other drugs only; [] No drugs

Results
The place of psychotropic drug exposure is visually summarised in Fig. 1 , which sets out the overall intercountry variability of all drug use in pregnancy. The denominators of each population and more precise quantitative information on women receiving psychotropics are presented in Table 2 . The 520 "exposed" women (3.5 %) reported 562 courses of psychotropic drugs, a minority of which included two (6.7 %) or three or more (0.6 %) products. A slightly higher proportion of psychotropics rather than of all other drugs was prescribed by the gynaecologist (84.7 % vs 73 %), while closely comparable frequencies were found for general practitioners (10.7% vs 12%); a psychiatrist was the prescriber in 3.2 % of the cases; selfmedication was reported for 1.4 % of exposures (6 % of all drugs). Neither pharmacists nor midwives were associated with the prescription of psychotropics (they contributed 1% and 5 %, respectively, to all prescriptions). Benzodiazepines (BDZ) accounted for the greatest majority of exposures (444/520 women, 459/562 courses), diazepam being the single most prescribed individual drug (84 % of all BDZ exposures).
The largest proportion of BDZ use was confined to the third trimester (171/444, 38.5 %); 143/444 received BDZ in the second trimester (98 of them continued their use into the third trimester); 69/444 reported BDZ consumption in the first trimester (17 continued into the second, and 5 resumed use in the third trimester); 61/444 reported use throughout pregnancy.
Neuroleptics were prescribed to 83 women, concentrated (67/83) in three countries (Czechoslovakia, 34 women, 9.1% of the entire sample from this country; Brazil, 16 women, 1.7 %; India, 17 women, 1.2 %); the use of promazine as an antiemetic was reported in 17 cases; in only 15 cases was use of neuroleptics associated with a psychiatric indication. Antidepressant treatment was reported by only 17 women (0.1%), 11 of whom were already receiving them before pregnancy (lithium treatment was reported in 2cases). Only 31/444 were "chronic" users of benzodiazepines, and 9/83 of neuroleptics.
Comparison of the information derived from the questions on drug exposures and related problems en- The "old" denomination in our study covers groups from Croatia and Serbia, respectively (see Authorship) countered during pregnancy shows that 130/182 women reporting anxiety disorders (71.4 % ) and 73/158 (46.2 %) with sleeplessness received BDZ. The other most frequently associated indications for BDZ use were: threatened abortion, which was reported in only two countriesYugoslavia and Czechoslovakia (79 and 6 women respectively); and pregnancy-induced hypertension, with 51 women exposed out of the overall 381 cases (29 of the women were concentrated in Yugoslavia, Brazil and India, but with occasional reports from the remaining countries). Preterm labour was also reported as an indication in two countries (Yugoslavia and Czechoslovakia with 3 and 6 cases, respectively); and pain was associated with BDZ use in 13 cases across the whole study sample.
B D Z exposure and maternal characteristics
Visual inspection of the intercountry heterogeneity set out in Fig. 1 and Table 2 suggests that "cultural" patterns or attitudes were the preeminent determinants of psychotropic drug exposure. These variables appeared to be more important than geographical heterogeneity, which itself could be an indicator of different reproductive patterns and health care organisation. For purely exploratory purposes, it seemed useful to analyse the exposure to BDZ as it occurred in geographical subgroupings which were expected to be homogeneous, because of their reproductive and health care characteristics. Two baseline characteristics of the women (age and education), two indicators of the intensity of care during pregnancy, (number of control visits and of ultrasound examinations), and three habits frequently reported as indicators of risk awareness during pregnancy were related to BDZ use (Table 3) . Whilst, as noted in the Methods section, formal statistical assessment would be inappropriate (and most subgroups were very small), it is interesting to note that the differences in rates seemed to coincide with circumstances (age, excess of ultrasound examinations) which the prescriber may see as indicating "at risk" pregnancies.
Discussion
The degree of representativeness of the population included in the DUP study, with respect to the hospitalbased cohorts of women delivering in the various participating countries has been discussed and documented in the general papers on the DUP results [18, 20] . Similarly, the reliability of the information collected by the interviews method using the combined sources of standardised questionnaires and medical records can be considered acceptable in view of the aims of the study. The point was not to strive for maximum completeness, as would be the case, for instance, in studies looking for causal relationships between exposures and malformations, but to assure a good degree of comparability throughout the various settings in which data were collected. The active responsibility of national coordinators, who checked the consistency of the results after having supervised the training and work of the interviewers, gives further reassurance about the ade-499 quacy of these findings as a satisfactory data base on which the following comments are based [18, 23] . Overall, the prevalence of psychotropic drug use (3.5 %) appears to be consistent with the most published surveys [16, 17] , confirming the down trend with respect to older data from the 1960s and 1970s [7] [8] [9] [10] [11] [12] [13] [14] [15] . Such a decrease applies not only to psychopharmological agents but to all drug use in pregnancy [1] . The most interesting finding, however, is the considerable heterogeneity found between the countries (Table 2 and Fig. 1 ). The differences were large enough to be compatible with all the frequencies documented over the 30 years of studies reported in Table 1 . Even more interesting is the fact that great variability was also found amongst countries which would be expected to share similar medical and cultural patterns, e. g. Norway versus Sweden, Denmark and Finland (where comparable degrees of completeness of recall-reporfing could also be assumed), as well as among the Southern European countries, e. g. Spain, Italy, Monaco and Malta. Epidemiologically, this underlying overall heterogeneity is more important than the finding of clusters of "excess" use of certain drug classes in any one of the countries mentioned in the results. Such clusters point to local factors, which should be investigated by ad hoc studies, as they may depend on specific "schools" or practices. Another informative finding was the very low overall prevalence of use of psychotropics other than BDZ: if the clusters found in certain countries were excluded, the data show that in a general sample of pregnant women problems requiring specific psychiatric treatment were an exceptional finding. The focus, therefore, is almost exclusively on BDZ (interesfingly, the oldest compound diazepam was by far the most commonly prescribed BDZ, as if the rule of relying on the most traditional remedies for pregnancy were being observed, contrary to general market trends and pharmacological indications for shorter acting molecules).
As reported in the literature about the controversial relationship of BDZ to malformations [24--34] , fewer than 1/3 of exposures occured during the first trimester (130/444 women, 0.9 % of the entire DUP population), and furthermore, regular use throughout pregnancy was reported by only 61 cases (0.4 %). To give a more direct idea of the public education and health implications of the above findings, it is useful to use the data from Italy, for which a large population was included in the study (5222 women). Of the 580,000 women who delivered a live birth in 1991 in Italy, only 1666 and 333 were estimated to have received BDZ respectively during the first trimester and throughout pregnancy. The present study collected data on malformations, whose overall frequency was found to be very closely comparable to the reported rates (3 %). A stated above, this survey was not orientated to the exploration of the relationship between drug treatment and outcome. As purely factual information, it may be useful to report that 2/61 women exposed throughout pregnancy (3.2 %), and 4/130 who had received BDZ during the first trimester (3.1%), reported malformations (no "cluster" effect was observed with respect to the types of malformations).
When considering the reasons for their prescription, BDZ appeared to be the proposed solution for the target disorders, namely anxiety and sleep problems in approximately 2/3 and 1/a of the cases. A multivariate analysis to explore the coincidence of these groups of women with those shown as being at higher risk in Table 3 (at least as perceived by the prescriber) would not yield stable estimates, because of the small size of the index subpopulations compared to the number of variables which should be included in the model. In any case, it would be incorrect to attempt any speculation on the degree of appropriateness of those prescriptions: the information necessary to look at that issue could be collected with complex, ad hoc protocols, as the problem of the clinical benefit/risk balance of these drugs for individual patients largely remains an unsettled question both during and outside pregnancy [35] .
There is now little doubt that, epidemiologically, BDZ represent cultural as well as iatrogenic problems for chronic users [36, 37] . On the other hand, in the light of the substantially reassuring available information about the teratogenic risks of BDZ, it seems reasonable to expect that 1.4 % of pregnant women might justifiably require some pharmacological help to cope with problems of anxiety and sleep.
Conclusions
The DUP study included a number of women which equaled the sum of all the surveys so far published (with the exclusion of the Perinatal Project [7] ; Table 1 ). The limitations and the importance of such large observational studies are well-known [38] .
The emerging profile of psychotropic drug exposure during pregnancy does not appear to be worrying. Small clusters of problems do exist, but they should be faced on a local basis, and there can be no general recommendations without knowledge of the underlying factors. It is likely that the anxiety generated by the use of this emotionally ambiguous class of drugs will remain for some women and prescribers. The availability of dedicated drug information centres may represent a useful resource for these individuals, most of whom are facing the real or perceived problem for which psychotropics are prescribed [39] . Because of their role, gynaecologists must be well informed, not only to minimise useless prescribing, but also to provide informed counselling. The very small minorities who are exposed to "needed" psychotropic therapies should not only receive appropriate comprehensive care, but should also be included in specific collaborative studies, to provide currently unavailable epidemiological data on the benefit/risk profile of those treatments.
The positive experience of a comprehensive undertaking, such as DUR might be periodically replicated with a focus on psychotropics, in order to monitor the evolution of this field of knowledge and care, and to provide reliable information for women and society.
